Investigational drug · Phase 3
CVN424
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Parkinson Disease, Parkinson's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "CVN424"
First trial start
2023
Sep 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CVN424", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "CVN424" as an intervention, largest first.
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsPivotal-lookingActive, not recruiting
CerevanceIndustry
NCT06553027 · 330 participants (planned) · Start Sep 20, 2024 · Primary completion Aug 2026
Drug: CVN424 75 mg; CVN424 150 mg and 1 more · For: Parkinson Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Aliso Viejo, California · 94 sites in all
- Study of CVN424 in Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingCompleted
Cerevance Beta, Inc.Industry
NCT04191577 · 136 participants · Start Dec 2, 2019 · Primary completion Nov 6, 2021
Drug: CVN424 Low Dose; CVN424 High Dose and 1 more · For: Parkinson Disease
Sites: Long Beach, California; Pasadena, California; Boca Raton, Florida · 21 sites in all
- Study of CVN424 in Healthy SubjectsCompleted
Cerevance Beta, Inc.Industry
NCT03657030 · 64 participants · Start Sep 18, 2018 · Primary completion Mar 1, 2019
Drug: CVN424; Placebo · For: Healthy
Sites: Austin, Texas
Cerevance Beta, Inc.Industry
NCT06006247 · 64 participants · Start Sep 11, 2023 · Primary completion Jan 30, 2025
Drug: CVN424 150 mg; Placebo · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 42 sites in all
Cerevance Beta, Inc.Industry
NCT05635461 · 32 participants · Start Oct 9, 2022 · Primary completion Nov 11, 2022
Drug: CVN424 · For: Parkinson's Disease
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12.
Tian X, Ali S, Addiah-Nickson JA, et al. · J Med Chem 2026
- CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease.
Tian X, Ali S, Allen JA, et al. · J Med Chem 2026
- Motor fluctuations in Parkinson disease - a mini-review of emerging drugs.
Gros P, Armengou Garcia L, Fox SH · Expert Opin Emerg Drugs 2025
- Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson's disease.
Barekatain M, Johansson LC, Lam JH, et al. · Sci Signal 2024
- CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.
Brice NL, Carlton M, Margolin DH, et al. · EClinicalMedicine 2024
- A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
Margolin DH, Brice NL, Davidson AM, et al. · J Pharmacol Exp Ther 2022
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
- AP-472Phase 21 trial
Appello Pharmaceuticals, Inc. · Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.